Home/Filings/4/0001562180-25-002636
4//SEC Filing

PATUSKY CHRISTOPHER 4

Accession 0001562180-25-002636

CIK 0001082554other

Filed

Mar 19, 8:00 PM ET

Accepted

Mar 20, 6:11 PM ET

Size

21.2 KB

Accession

0001562180-25-002636

Insider Transaction Report

Form 4
Period: 2025-03-19
Transactions
  • Sale

    Common Stock

    2025-03-19$312.22/sh736$229,7922,299 total
  • Exercise/Conversion

    Stock Option

    2025-03-195,0000 total
    Exercise: $175.43From: 2016-06-26Exp: 2025-06-26Common Stock (5,000 underlying)
  • Exercise/Conversion

    Common Stock

    2025-03-19$175.43/sh+5,000$877,1505,900 total
  • Sale

    Common Stock

    2025-03-19$310.80/sh457$142,0353,035 total
  • Sale

    Common Stock

    2025-03-19$313.14/sh1,299$406,7691,000 total
  • Sale

    Common Stock

    2025-03-19$307.73/sh300$92,3205,600 total
  • Sale

    Common Stock

    2025-03-19$308.82/sh1,780$549,7013,820 total
  • Sale

    Common Stock

    2025-03-19$309.73/sh328$101,5913,492 total
  • Sale

    Common Stock

    2025-03-19$313.77/sh100$31,377900 total
Holdings
  • Common Stock

    (indirect: By Trust)
    1,100
Footnotes (7)
  • [F1]This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 27, 2024.
  • [F2]This transaction was executed in multiple trades at prices ranging from $307.32 to $308.125. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F3]This transaction was executed in multiple trades at prices ranging from $308.44 to $309.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]This transaction was executed in multiple trades at prices ranging from $309.48 to $310.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F5]This transaction was executed in multiple trades at prices ranging from $310.48 to $310.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F6]This transaction was executed in multiple trades at prices ranging from $311.68 to $312.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F7]This transaction was executed in multiple trades at prices ranging from $312.735 to $313.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Issuer

UNITED THERAPEUTICS Corp

CIK 0001082554

Entity typeother

Related Parties

1
  • filerCIK 0001231427

Filing Metadata

Form type
4
Filed
Mar 19, 8:00 PM ET
Accepted
Mar 20, 6:11 PM ET
Size
21.2 KB